Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on German News Wire.
Press releases published on June 12, 2025
Leading Global Manufacturer Confirms First Batch of Pilot Plant Material Tested is Fumed Silica
GlobeNewswire
·
June 12, 2025
MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to inform shareholders …
PyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global Supplier
GlobeNewswire
·
June 12, 2025
MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and …
Un fabricant de premier plan confirme que le premier lot de matériau de l’usine pilote testé est de la silice pyrogénée
GlobeNewswire
·
June 12, 2025
MONTRÉAL, 12 juin 2025 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), une entreprise technologique spécialisée dans l’innovation en matériaux avancés et le développement de procédés critiques informe …
BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an
GlobeNewswire
·
June 12, 2025
Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der Umsetzung von BioNTechs Onkologie-Strategie Die Übernahme …
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
GlobeNewswire
·
June 12, 2025
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement …